Seeking Alpha

SciClone Pharmaceuticals (SCLN +16.8%) are soaring after its Q2 bottom line topped Street...

SciClone Pharmaceuticals (SCLN +16.8%) are soaring after its Q2 bottom line topped Street estimates late yesterday. Total revenue jumped 22% Y/Y, helped by a 27% increase in sales of its drug Zadaxin, plus revenue growth from its primary care and oncology businesses in China and positive synergies from its recent takeover of NovaMed Pharmaceuticals.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs